Core Viewpoint - The company Baiotai has completed clinical trials for the subcutaneous formulation of tocilizumab and is actively preparing for the submission of applications both domestically and for overseas authorization [1] Group 1 - The subcutaneous formulation of tocilizumab has completed clinical trials [1] - Baiotai is currently working on preparations for application submissions [1]

Core Viewpoint - The company Baiotai has completed clinical trials for its subcutaneous formulation of Tocilizumab and is actively preparing for the submission of relevant applications [2] Group 1 - The subcutaneous formulation of Tocilizumab has successfully completed clinical trials [2] - The company is currently advancing preparations for application submission [2]

Group 1 - The core point of the article is that the company Baiotai (688177.SH) has completed clinical trials for the subcutaneous formulation of tocilizumab and is actively preparing for the submission of relevant applications [1] Group 2 - Investors inquired about the progress of the subcutaneous tocilizumab and the timeline for domestic application and overseas authorization [1]